| Market revenue in 2025 | USD 480.1 million |
| Market revenue in 2033 | USD 1,217.3 million |
| Growth rate | 12.71% (CAGR from 2026 to 2033) |
| Largest segment | Hereditary non-cancer testing |
| Fastest growing segment | Hereditary Non-cancer Testing |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
| Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
Breast cancer is the most frequent malignancy in Spanish women, with an incidence of around 85 cases per 100,000 women, as per International Agency for Research on Cancer data. The Spanish Medical Oncology Society (SEOM) laid down clinical criteria for selection of inherited breast cancer patients through a clinical guideline that would be eligible for genetic testing.
European Society for Medical Oncology provides its own guidelines that focus on prevention and screening of cancer among individuals known to harbor pathogenic BRCA1/BRCA2 mutations. The presence of these mutations’ accounts for majority of hereditary breast and ovarian cancer syndromes.
Spanish regulatory framework for hereditary testing of inherited cancer cases is expected to streamline cancer testing in Spain, which, in turn, increases the adoption of accurate and improved testing solutions across the Spanish market.
Publish Date: Nov 19, 2025
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Quest Diagnostics Inc | View profile | 48,000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | www.questdiagnostics.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Myriad Genetics Inc | View profile | 2,700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | www.myriad.com |
| Natera Inc | View profile | 3,293 | 13011 McCallen Pass, Building A Suite 100, Austin, TX, United States, 78753 | www.natera.com |
| The Cooper Companies Inc | View profile | 15,000 | 6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, United States, 94583 | www.coopercos.com |
| Invitae Corp | View profile | 1,700 | 1400 16th Street, San Francisco, CA, United States, 94103 | www.invitae.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Hereditary Testing Market will help companies and investors design strategic landscapes.
Hereditary Non-Cancer Testing was the largest segment with a revenue share of 78.36% in 2025.
Horizon Databook has segmented the Spain hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2021 to 2033.
Breast cancer is the most frequent malignancy in Spanish women, with an incidence of around 85 cases per 100,000 women, as per International Agency for Research on Cancer data. The Spanish Medical Oncology Society (SEOM) laid down clinical criteria for selection of inherited breast cancer patients through a clinical guideline that would be eligible for genetic testing.
European Society for Medical Oncology provides its own guidelines that focus on prevention and screening of cancer among individuals known to harbor pathogenic BRCA1/BRCA2 mutations. The presence of these mutations’ accounts for majority of hereditary breast and ovarian cancer syndromes.
Spanish regulatory framework for hereditary testing of inherited cancer cases is expected to streamline cancer testing in Spain, which, in turn, increases the adoption of accurate and improved testing solutions across the Spanish market.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into Spain hereditary testing market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
